The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 351:2013-2015 November 4, 2004 Number 19
NextNext

Nevirapine plus Zidovudine to Prevent Mother-to-Child Transmission of HIV

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Lallemant, M.
-Related Article
by Jourdain, G.
-PubMed Citation
To the Editor: The articles by Lallemant et al. and Jourdain et al. (July 15 issue)1,2 highlight a dilemma. Should we impair the health of one patient to help another patient? Of the women receiving nevirapine, 32 percent showed resistance mutations to nonnucleoside reverse-transcriptase inhibitors (NNRTI) at 10 days post partum.2 However, viral rebound may occur 21 days3 after receipt of the drug and result in an even higher rate of resistance mutations to NNRTI. Of the mothers receiving zidovudine monotherapy, 6.3 percent transmitted the human immunodeficiency virus (HIV) to their infants, as compared with 2.8 percent of mothers treated . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.